MF Global Upgrades AstraZeneca plc (AZN) to Buy
More News related to AZN
- Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu
- AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
- Abbott (ABT) and AstraZeneca (AZN) to Co-Promote CRESTOR(R)
- Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
- MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alpha
MF Global upgrades AstraZeneca plc (NYSE: AZN) from Neutral to Buy and raises thier price target from 2350p to 2600p.
AstraZeneca PLC discovers, develops, manufactures, and markets prescription pharmaceuticals, biologics, and vaccines in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide.
Related Categories
UpgradesStocks Mentioned
-0.54Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
